glp-1 shortages New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although ended in 2025, some facilities may still be producing these drugs at scale. Our GLP-1 receptor agonists shortage expected

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should discuss this risk with their healthcare provider before considering semaglutide

The drug isn't burning fat

Integration of multi-omics with single-cell approaches can identify key pathways and network hubs influenced by SIRT1, supporting the development of optimized intervention strategies

Theres a wide range of vitamins, minerals and essential nutrients commonly associated with heart health and theyre probably already on the menu

Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: A randomized, Double-Blind, Placebo-Controlled phase 2 trial